- Home
- KRKR vs BIAF Comparison
KRKR vs BIAF Comparison
Compare KRKR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- BIAF
- Stock Information
- Founded
- KRKR 2010
- BIAF 2014
- Country
- KRKR China
- BIAF United States
- Employees
- KRKR N/A
- BIAF N/A
- Industry
- KRKR Business Services
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KRKR Consumer Discretionary
- BIAF Health Care
- Exchange
- KRKR Nasdaq
- BIAF Nasdaq
- Market Cap
- KRKR 10.6M
- BIAF 9.3M
- IPO Year
- KRKR 2019
- BIAF 2022
- Fundamental
- Price
- KRKR $5.55
- BIAF $2.04
- Analyst Decision
- KRKR
- BIAF Hold
- Analyst Count
- KRKR 0
- BIAF 1
- Target Price
- KRKR N/A
- BIAF N/A
- AVG Volume (30 Days)
- KRKR 7.7K
- BIAF 1.2M
- Earning Date
- KRKR 09-26-2025
- BIAF 11-14-2025
- Dividend Yield
- KRKR N/A
- BIAF N/A
- EPS Growth
- KRKR N/A
- BIAF N/A
- EPS
- KRKR N/A
- BIAF N/A
- Revenue
- KRKR $30,966,526.00
- BIAF $7,681,059.00
- Revenue This Year
- KRKR $182.55
- BIAF N/A
- Revenue Next Year
- KRKR N/A
- BIAF $20.04
- P/E Ratio
- KRKR N/A
- BIAF N/A
- Revenue Growth
- KRKR N/A
- BIAF 4.99
- 52 Week Low
- KRKR $2.76
- BIAF $1.91
- 52 Week High
- KRKR $21.36
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- KRKR 49.37
- BIAF 44.26
- Support Level
- KRKR $4.87
- BIAF $1.91
- Resistance Level
- KRKR $5.82
- BIAF $2.33
- Average True Range (ATR)
- KRKR 0.39
- BIAF 0.18
- MACD
- KRKR 0.06
- BIAF -0.03
- Stochastic Oscillator
- KRKR 88.37
- BIAF 33.33
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.